Olmesartan/Amlodipin/Hct Viatris (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

• Olmesartan/Amlodipin/HCT is indicated for the management of hypertension, acting on the renin‑angiotensin system, calcium channels, and diuretic pathways.
• Essential hypertension: provides greater blood pressure reduction than monotherapy.
• Secondary hypertension: assists in controlling blood pressure when multiple mechanisms are involved.
• Hypertension with edema: amlodipine mitigates vascular tone while olmesartan reduces angiotensin‑II effects, improving overall control.

• Olmesartan medoxil selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Amlodipine inhibits L‑type calcium channels in vascular smooth muscle, causing arterial dilation. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit NaCl reabsorption, promoting diuresis and reducing plasma volume. The combined actions produce additive blood‑pressure lowering effects.

Common Side Effects

• Dizziness or light‑headedness.
• Headache.
• Peripheral edema, especially of the lower limbs.
• Flushing or warmth sensation.
• Fatigue or mild weakness.
• Nausea or abdominal discomfort.

Serious or Rare Side Effects

• Angioedema involving face, lips, tongue or airway.
• Severe hypotension leading to fainting.
• Acute renal impairment or sudden rise in serum creatinine.
• Electrolyte disturbances such as hyponatremia or hypokalemia.
• Hepatic dysfunction with elevated transaminases.
• Pancreatitis presenting with abdominal pain and vomiting.

• Before initiating therapy, clinicians should consider several safety aspects.
• Monitor renal function: assess serum creatinine and eGFR at baseline and periodically.
• Assess electrolytes: watch for hyponatremia, hypokalemia, or hyperkalemia due to the thiazide component.
• Avoid in severe hepatic impairment: dose adjustment may be required.
• Use caution in aortic stenosis: risk of marked hypotension.
• Pregnancy: contraindicated in the second and third trimesters because of fetal toxicity.
• Store at ambient temperature: keep below 25°C, protect from moisture and light, retain in original packaging.

Olmesartan/Amlodipin/HCT may interact with several medicines.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: increased risk of renal impairment.
• Potassium‑sparing diuretics or supplements: potential hyperkalemia.
• Lithium: elevated lithium concentrations and toxicity.

Moderate Interactions (Monitor Closely)

• ACE inhibitors: additive risk of hyperkalemia and renal dysfunction.
• NSAIDs: may blunt antihypertensive effect and affect renal function.
• Other antihypertensives: risk of additive hypotension; monitor blood pressure closely.